The Pharmacist

MAY 26, 2023

People aged between 50 and 64 years old will not be eligible for a free flu vaccination in the 2023/24 season, the government announced yesterday in its flu vaccination programme letter.

Communication 98

Communication Vaccines 98

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Communication 81

Communication Vaccines HIPAA Documentation 81

Express Pharma

AUGUST 27, 2024

Indian Immunologicals Limited (IIL) has announced the development of a live-attenuated, needle-free intranasal booster vaccine against SARS-CoV-2. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over.

Vaccines 104

Vaccines Immunity Immunization Communication 104

Pharma Times

NOVEMBER 8, 2023

Communicable diseases account for 50% of all deaths in LMICs - News - PharmaTimes

Communication 148

Communication Vaccines 148

pharmaphorum

NOVEMBER 19, 2020

Amid the turmoil and the race to not only find a vaccine but also help to care for those who are battling the long-term effects of COVID-19, healthcare organisations need to sharpen their communication skills. Good, empathetic design allows the science to shine.

Communication 95

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 95

pharmaphorum

MAY 19, 2022

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 124

Vaccines Immunity Immunization Communication 124

World Pharma News

AUGUST 26, 2024

A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. New Griffith University research, published in Nature Communications, has been testing the efficacy of delivering a COVID-19 vaccine via the nasal passages.

Vaccines 90

Vaccines Communication 90

STAT

OCTOBER 21, 2024

A little communication can go a long way. The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as Allegra, Dulcolax, and IcyHot. As always, you are invited to join us.

Vaccines 278

Vaccines Communication 278

European Pharmaceutical Review

MARCH 6, 2023

The first clinical trial of any subunit tuberculosis (TB) vaccine in a temperature-stable form has found that ID93+GLA-SE, a freeze-dried vaccine, was safe. The recombinant subunit vaccine is made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant.

Immunity 103

Immunity Immunization Vaccines Communication 103

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunity Immunization 111

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccines 115

Vaccines Communication 115

pharmaphorum

DECEMBER 17, 2020

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Vaccines 97

Vaccines Communication Immunity Immunization 97

European Pharmaceutical Review

AUGUST 15, 2022

According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK. We are witnessing the largest sustained drop in childhood immunisation in a generation.

Vaccines 98

Vaccines Communication 98

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunity Immunization Communication 98

STAT

FEBRUARY 1, 2024

Novavax is on thin ice Novavax, the company whose corporate missteps repeatedly sidelined an effective Covid-19 vaccine, is relying on demand for booster doses to remain solvent. Novavax won’t disclose its revenue until later this month, but its latest communications don’t exactly inspire confidence.

Drug Pricing 319

Drug Pricing Vaccines Communication Drug Development 319

Pharmafile

JANUARY 23, 2023

Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ the vaccine is the first of its kind to be developed in India. read more

Vaccines 98

Vaccines Communication 98

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines 98

Vaccines Documentation Immunity Immunization 98

Pharmafile

MARCH 2, 2023

Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine candidate for older adults. This support is ahead of an official FDA approval for the company’s vaccine. GSK has shared that a final decision is expected to be made by the FDA ahead of the 3 May. read more

Vaccines 98

Vaccines Communication 98

Digital Pharmacist

AUGUST 21, 2023

The most effective preventive measure against the flu is getting an annual flu vaccine. Getting Vaccinated for the Flu The CDC says ideally, everyone who is eligible for a flu vaccine should be vaccinated by the end of October – the ideal time to get vaccinated being September or October.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Eye on FDA

DECEMBER 1, 2020

In my last posting on preparedness for a post-vaccination world I touched on some of the questions facing employers in general – policy questions that should be considered now for the eventualities of later. COVID-19 has cast a particularly harsh light on this fact where minorities in the U.S.

Vaccines 66

Vaccines Communication 66

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”

Vaccines 126

Vaccines Immunity Immunization Communication 126

Pharmafile

SEPTEMBER 9, 2022

A new malaria vaccine could be pivotal in the fight against the deadly disease. This vaccine has been developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab. read more.

Vaccines 81

Vaccines Communication 81

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

Pharmacy Times

NOVEMBER 16, 2022

Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients. Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E.

Vaccines 52

Vaccines Communication 52

Express Pharma

JUNE 20, 2023

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Finally, public engagement in research has to be sought through informal group sessions communicating the purpose of the human research in plain language.

Immunity 105

Immunity Immunization Vaccines Hospitals 105

Pharmacy Times

AUGUST 10, 2023

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

Vaccines 49

Vaccines Communication 49

pharmaphorum

MARCH 4, 2021

Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group. . France has said the vaccine can be used in people aged up to 74, rather than the entire over 65s age group. million doses unused.

Vaccines 64

Vaccines Communication 64

Pharmafile

JANUARY 13, 2023

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

Vaccines 78

Vaccines Communication 78

Pharmafile

DECEMBER 23, 2022

BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which aims to develop a multi-antigen malaria vaccine.

Vaccines 80

Vaccines Communication 80

Pharmaceutical Technology

DECEMBER 18, 2022

The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination. 1273.214, a bivalent Omicron-targeting Covid-19 vaccine of the company. 5), mRNA-1273.

Vaccines 121

Vaccines Communication 121

Pharmacy Times

NOVEMBER 10, 2022

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, leads a discussion on the challenges subvariants of SARS-CoV-2 present in terms of vaccination and approaching optimal communication to the public surrounding vaccination.

Vaccines 49

Vaccines Communication 49

pharmaphorum

JANUARY 20, 2021

One in 11 adults aged over 65 have reported a lack of willingness to receive a COVID-19 vaccine, according to a US-based survey. of participants reported they were very willing to receive a COVID-19 vaccine, 27.8% Further work is also needed to identify why different demographic groups have differing attitudes to the vaccine.

Vaccines 98

Vaccines Communication 98

pharmaphorum

AUGUST 12, 2022

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. — Kidney Care UK (@kidneycareuk) August 12, 2022.

Vaccines 145

Vaccines Communication 145

European Pharmaceutical Review

JUNE 27, 2022

GSK now has more than 30 potential new vaccines and medicines in 13 high-burden infectious diseases to accelerate, and we must work collectively with urgency to bring these potentially life-saving innovations to people that need them.”. Europe’s Healthier Together initiative. A guidance document has been released to support these activities.

Vaccines 110

Vaccines Communication Documentation Compounding 110

Putting Patients First Blog

SEPTEMBER 28, 2023

Fall is pumpkin spice and vaccine season! September 28, 2023 By: Bhriana Onuoha, Senior Coordinator, Communications The fall season is in full swing. It’s easy to get swept up in the busyness of the season, but it is important for your health, and the health of your family, to get the appropriate vaccinations.

Vaccines 52

Vaccines Immunity Immunization Communication 52